IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) Attorney Docket No.: SOEI0009
Jun KASHIMURA et al.) Confirmation No. 2759
Serial No.: 10/715,125) Group Art Unit: 1761
Filed: November 18, 2003) Examiner: Unassigned
For: REDUCER OF BLOOD GLUCOSE LEVEL INCREASE REDUCER OF BODY FAT ACCUMULATION AND FOOD MATERIAL) Date: May 10, 2006)))

INFORMATION DISCLOSURE STATEMENT

MAIL STOP: AMENDMENT

United States Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, this Information Disclosure Statement in connection with the above-identified application is being filed in accordance with 37 C.F.R. §1.97(b):

- within three months of the filing date of this application (not a C.P.A.);

 within three months of the date of entry of the National Stage;
- X before the mailing date of a first Office Action on the merits; or
- before the mailing of a first Office Action on the merits of, after the filing of a Request for Continued Examination (RCE) under §1.114.

A copy of each non-U.S. document identified on the attached Forms PTO/SB/08A and PTO/SB/08B is attached, however, in accordance with Official Gazette Notice dated August

-1- o3-2006

5, 2003, copies of the U.S. patents and patent application publications are not attached.

Attached is a copy of a Notice of Rejection issued in the corresponding Chinese application. Since all of the documents cited herein, that were not previously cited in an Information Disclosure Statement, were cited in said Notice of Rejection, it is believed that the relevancy of each document cited is clear from the Notice of Rejection. Accordingly, no further comment with regard to the disclosure of this documents is believed to be required.

The Notice of Rejection was mailed on March 3, 2006, less than three months prior to the filing of this Information Disclosure Statement. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

It is respectfully requested that the attached documents be considered and officially cited, and that the Examiner initial a copy of Forms PTO/SB/08A and PTO/SB/08B, and return them to the undersigned to indicate that the documents have been considered.

-2- 03-2006

It is believed that the present Information Disclosure Statement complies with the requirements of 37 C.F.R. §§ 1.97-8, but should the filing of this paper necessitate a fee, the Director is hereby authorized to charge the necessary fee to Deposit Account No. 50-1281.

Respectfully submitted,

GRIFFIN & SZIPL, PC

Joerg-Uwe Szipl

Registration No. 31,799

GRIFFIN & SZIPL, PC Suite PH-1 2300 Ninth Street, South Arlington, VA 22204

Telephone: (703) 979-5700 Facsimile: (703) 979-7429 E-mail: gands@szipl.com Customer No.: 24203

/S.N./

07/02/2008 /Shyam Nathan/

- **3** - 03-2006